Velocity is the world's leading integrated site organization.
Sponsors and CROs trust Velocity to deliver high-quality clinical trial data and patient care with unprecedented efficiency.
Simplify everything from site selection to study close-out
Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.
News
An Interview with Matthew Wenker, MD on the People-First Principles that Shape Good Clinical Research
Over the course of his career, Matthew Wenker, MD, has moved from hospital wards to Phase I units and, eventually, to leading research across three Velocity sites in Cincinnati. Along … Read more
Lilly’s Once-Weekly Insulin Efsitora Demonstrated A1C Reduction and Safety Profile Consistent With Daily Insulin in Phase 3 Trials
Across multiple Phase 3 trials, Eli Lilly and Company’s once-weekly insulin efsitora alfa matched daily basal insulin in A1C reduction and demonstrated a similar safety profile. “The novel fixed-dose regimen … Read more
Positive Topline Results Announced for ACCESS Studies for Aleniglipron (Oral GLP-1 RA)
Congratulations to the Structure Therapeutics team for announcing positive topline data from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist. Julio Rosenstock, MD, Chair of the ACCESS … Read more
Henrik Watz, MD, PhD, Authors Results for the First Clinical Trial of Glasmacinal (EP395) in COPD Patients
Henrik Watz, MD, PhD, is the chief investigator and author of trial results for EpiEndo’s clinical trial of glasmacinal (EP395). Results indicated that glasmacinal reduced neutrophilic inflammation in COPD patients … Read more